SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers

This is a randomized Phase II study of standard of care (SOC) chemotherapy monotherapy vs. SOC chemotherapy combined with tocilizumab in in Black and non-Black patients with metastatic triple negative or ER low breast cancer.

Trial Details

NCT ID
NCT05846789
Phase
PHASE2
Sponsor
Kathy Miller
Status
RECRUITING
Cancer Type
Triple Negative (TNBC) Breast Cancer
Interventions
  • SOC Chemotherapy
  • Tocilizumab
Locations (sample)
  • Atlanta, Georgia, United States|33.749,-84.38798
  • Carmel, Indiana, United States|39.97837,-86.11804
  • Indianapolis, Indiana, United States|39.76838,-86.15804
  • Indianapolis, Indiana, United States|39.76838,-86.15804
  • Buffalo, New York, United States|42.88645,-78.87837

Key Eligibility Criteria

  • ≥ 18 years old at the time of informed consent
  • Ability to provide written informed consent and HIPAA authorization
  • Locally recurrent (not amenable to local therapy with curative intent) or metastatic breast cancer that is triple negative or ER-low (ER and PR ≤ 9…
  • Received up to 2 prior therapies for metastatic disease

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →